OTCM
PPCB
Market cap26mUSD
Jun 10, Last price
8.00USD
1D
6.67%
1Q
18.52%
IPO
-100.00%
Name
Propanc Biopharma Inc
Chart & Performance
Profile
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 1,536 | 1,834 | 2,019 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,536) | (1,834) | (2,019) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (129) | (130) | (55) | |||||||
Tax Rate | ||||||||||
NOPAT | (1,407) | (1,704) | (1,964) | |||||||
Net income | (1,821) -41.84% | (3,130) -6.85% | (3,360) 38.84% | |||||||
Dividends | (466) | (700) | ||||||||
Dividend yield | 198.64% | 272,241.01% | ||||||||
Proceeds from repurchase of equity | 23 | 25 | (667) | |||||||
BB yield | -1,301,736.06% | -10.53% | 259,364.43% | |||||||
Debt | ||||||||||
Debt current | 890 | 527 | 1,056 | |||||||
Long-term debt | 78 | 60 | 105 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 947 | 577 | 1,157 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (935) | (1,105) | (1,436) | |||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 942 | 1,114 | 1,491 | |||||||
FCF | (2,365) | 186 | (2,427) | |||||||
Balance | ||||||||||
Cash | 21 | 10 | 4 | |||||||
Long term investments | ||||||||||
Excess cash | 21 | 10 | 4 | |||||||
Stockholders' equity | (64,950) | (63,382) | (60,078) | |||||||
Invested Capital | 62,119 | 59,569 | 58,153 | |||||||
ROIC | ||||||||||
ROCE | 54.26% | 48.11% | 104.88% | |||||||
EV | ||||||||||
Common stock shares outstanding | 1 | 1,739 | 70 | |||||||
Price | 0.00 -99.07% | 0.14 3,573.47% | 0.00 -92.89% | |||||||
Market cap | 2 -100.00% | 235 91,149.08% | 257 | |||||||
EV | 947 | 811 | 1,162 | |||||||
EBITDA | (1,514) | (1,811) | (2,014) | |||||||
EV/EBITDA | ||||||||||
Interest | 666 | 533 | 569 | |||||||
Interest/NOPBT |